Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines

Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their inception. In the 2012 NCCN Guidelines for HL, PET scans are not recommended for interim restaging of patients with stage I to II favorable disease. After reevaluating the available evidence on the use of interim PET imaging, the panel recommends the use of diagnostic CT scan of involved sites for interim restaging after completion of chemotherapy for this group of patients. Maintenance rituximab for 2 years is included as an option for patients with stage IB to IIB or stage III to IV LPHL treated with rituximab alone in the first-line setting. Brentuximab vedotin is included as an option for patients with progressive disease or relapsed disease after second-line chemotherapy or high-dose therapy with autologous stem cell rescue.

  • 1

    ChesonBD. Role of functional imaging in the management of lymphoma. J Clin Oncol2011;29:18441854.

  • 2

    KuruvillaJKeatingACrumpM. How I treat relapsed and refractory Hodgkin lymphoma. Blood2011;117:42084217.

  • 3

    YounesABartlettNLLeonardJP. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med2010;363:18121821.

  • 4

    MaedaLSAdvaniRH. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol2009;21:397400.

    • Search Google Scholar
    • Export Citation
  • 5

    HutchingsMMikhaeelNGFieldsPA. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol2005;16:11601168.

    • Search Google Scholar
    • Export Citation
  • 6

    SherDJMauchPMVan Den AbbeeleA. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol2009;20:18481853.

    • Search Google Scholar
    • Export Citation
  • 7

    BarnesJALaCasceASZukotynskiK. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol2011;22:910915.

    • Search Google Scholar
    • Export Citation
  • 8

    StrausDJJohnsonJLLaCasceAS. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood2011;117:53145320.

    • Search Google Scholar
    • Export Citation
  • 9

    TerasawaTLauJBardetS. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol2009;27:19061914.

    • Search Google Scholar
    • Export Citation
  • 10

    GallaminiARigacciLMerliF. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica2006;91:475481.

    • Search Google Scholar
    • Export Citation
  • 11

    HutchingsMLoftAHansenM. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood2006;107:5259.

    • Search Google Scholar
    • Export Citation
  • 12

    GallaminiAHutchingsMRigacciL. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol2007;25:37463752.

    • Search Google Scholar
    • Export Citation
  • 13

    CerciJJPracchiaLFLinardiCC. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med2010;51:13371343.

    • Search Google Scholar
    • Export Citation
  • 14

    AdvaniRMaedaLLavoriP. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s disease. J Clin Oncol2007;25:39023907.

    • Search Google Scholar
    • Export Citation
  • 15

    MarkovaJKahramanDKobeC. Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma2012;53:6470.

    • Search Google Scholar
    • Export Citation
  • 16

    BonadonnaGBonfanteVVinianiS. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol2004;22:28352841.

    • Search Google Scholar
    • Export Citation
  • 17

    EngertAPlutschowAEichHT. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med2010;363:640652.

    • Search Google Scholar
    • Export Citation
  • 18

    AdvaniRHHoppeRTMaedaLS. Stage I-IIA non-bulky Hodgkin’s lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys2011;81:13741379.

    • Search Google Scholar
    • Export Citation
  • 19

    MeyerRMGospodarowiczMKConnorsJM. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol2005;23:46344642.

    • Search Google Scholar
    • Export Citation
  • 20

    MeyerRMGospodarowiczMKConnorsJM. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med2012;366:399408.

    • Search Google Scholar
    • Export Citation
  • 21

    EkstrandBCLucasJBHorwitzSM. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood2003;101:42854289.

    • Search Google Scholar
    • Export Citation
  • 22

    SchulzHRehwaldUMorschhauserF. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood2008;111:109111.

    • Search Google Scholar
    • Export Citation
  • 23

    AzimHAJrPruneriGCocorocchioE. Rituximab in lymphocyte-predominant Hodgkin disease. Oncology2009;76:2629.

  • 24

    JacksonCSirohiBCunninghamD. Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. Ann Oncol2010;21:20612068.

    • Search Google Scholar
    • Export Citation
  • 25

    FanaleMALaiCMMcLaughlinP. Outcomes of nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) patients treated with R-CHOP [abstract]. Blood2010;116:Abstract 2812.

    • Search Google Scholar
    • Export Citation
  • 26

    EichenauerDAFuchsMPluetschowA. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood2011;118:43634365.

    • Search Google Scholar
    • Export Citation
  • 27

    HorningSJBartlettNLBreslinS. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin’s disease (NLPHD) [abstract]. Blood2007;110:Abstract 644.

    • Search Google Scholar
    • Export Citation
  • 28

    AdvaniRHHorningSJHoppeRT. Frontline therapy of nodular lymphocyte predominant Hodgkin lymphoma with rituximab: the Stanford University experience [abstract]. Blood2011;118:Abstract 2686.

    • Search Google Scholar
    • Export Citation
  • 29

    LinchDCWinfieldDGoldstoneAH. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet1993;341:10511054.

    • Search Google Scholar
    • Export Citation
  • 30

    SchmitzNPfistnerBSextroM. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet2002;359:20652071.

    • Search Google Scholar
    • Export Citation
  • 31

    MoskowitzAJPeralesMAKewalramaniT. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol2009;146:158163.

    • Search Google Scholar
    • Export Citation
  • 32

    MoskowitzCHKewalramaniTNimerSD. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol2004;124:645652.

    • Search Google Scholar
    • Export Citation
  • 33

    SirohiBCunninghamDPowlesR. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol2008;19:13121319.

    • Search Google Scholar
    • Export Citation
  • 34

    ChenRWGopalAKSmithSE. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) [abstract]. J Clin Oncol2011;29(Suppl):Abstract 8031.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 327 327 53
PDF Downloads 35 35 6
EPUB Downloads 0 0 0